A plant-based COVID-19 vaccine candidate produced by a Quebec company showed promising interim results of a Phase 1 trial. There was a 100% response rate of subjects developing an antibody response following two doses of the candidate. The early trial had 180 healthy participants and based on results the company will move on to a more advanced Phase II/III trial.